<DOC>
	<DOCNO>NCT00694902</DOCNO>
	<brief_summary>This study first administration GSK610677 man . The main aim clinical study investigate safety tolerability different dose investigational medicinal product GSK610677 . 2 cohort 8 subject ( Cohorts I II ) enrol study . Individual subject cohort 3 treatment period . In treatment period , subject receive single inhale dose GSK610677 placebo . Predicted dos : 10 , 30 , 50 100 250 500ug.For individual subject cohort , minimum wash period least 10 day . In period safety tolerability data collect prior dose next level.After safety review meeting site sponsor follow administration 500 ug dose , decide add extra cohort ( Cohort III ) 8 subject administer 1000Âµg . Each subject Cohort III undergo screen visit , one treatment period , follow visit .</brief_summary>
	<brief_title>Single Dose Escalation Study FTIM Order Assess Safety Tolerability GSK610677</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Healthy determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range determine investigator clinical significance population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Subjects liver function value outside normal range always exclude enrolment . Male 18 50 year age . Subjects must agree use one contraception method list Section 8 . This criterion must follow time first dose study medication 7 day last dose study medication 5 terminal halflive last dose study medication , whichever longer . Body weight &gt; 50 kg BMI within range 19 29.9 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . QTcB QTcF &lt; 450 msec . Demonstrated ability use DISKUS inhaler device satisfactory repeatable manner judge investigator designee . Current nonsmoker , use inhaled tobacco product 12 month period precede screen visit total pack history &lt; 5 pack year ( pack year = ( number cigarette per day/20 ) x ( . year smoke ) ) . Screening prebronchodilator FEV1 &gt; 80 % predict FEV1/FVC ratio &gt; 0.7 . The subject positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Subject know HIV seropositive . History regular alcohol consumption within 6 month study define : average weekly intake great 21 unit average daily intake great 3 unit . One unit equivalent halfpint ( 220 mL ) beer 1 ( 25 mL ) measure spirit 1 glass ( 125 mL ) wine . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product , whichever longer . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56day period . Unwillingness inability follow procedure outline protocol . Subjects asthma history asthma . The subject respiratory symptom , include `` cold flu '' type symptom respiratory infection/symptoms within 4 week screen . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit grapefruit hybrid 7 day prior first dose study medication . Chronic liver biliary disease , history Gilbert 's syndrome . History increase liver function test upper limit normal past six month . Subjects keep due regulatory judicial order institution . Subject Investigator subinvestigator , research assistant , pharmacist , study coordinator , staff , relative thereof directly involve conduct study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>